

## Catalog #10-3658 Neratinib

CAS# 698387-09-6

(2E)-N-[4-[[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide; HKI-272

## Lot # E108322

A potent, irreversible inhibitor of HER2/ErbB2 receptor tyrosine kinase and EGFR kinase ( $IC_{50}$ 's= 59 nM and 92 nM, respectively). It suppresses receptor autophosphorylation and proliferation, blocks cell-cycle progression and inhibits HER2 signaling in of EGFR-dependent cancer cells and tumor xenograft models.<sup>1</sup> Neratinib inhibits proliferation of gefitinib-resistant non-small cell lung cancer cells expressing mutant EGFR.<sup>2</sup> Synergizes with dasatinib in HER2-positive cancer cells and xenografts.<sup>3</sup> It's been shown to also inhibit MST1 ( $IC_{50}$  = 37.7 nM).<sup>4</sup>

- 1) Rabindran et al. (2004), Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase; Cancer Res. **64** 3958
- 2) Kwak et al. (2005), Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib; Proc. Natl. Acad. Sci. USA **102** 7665
- 3) Conlon et al. (2024), Neratinib plus Dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo; Trans. Oncol. **49** 102073
- 4) Yun et al. (2008), The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP; Proc. Natl. Acad. Sci. USA **105** 20770

## **PHYSICAL DATA**

Molecular Weight: 557.05

 $\begin{array}{ll} \mbox{Molecular Formula:} & C_{30}\mbox{H}_{29}\mbox{CIN}_6\mbox{O}_3 \\ \mbox{Purity:} & >98\% \ (\mbox{HPLC}) \end{array}$ 

NMR: (Conforms)

Solubility: DMSO (4 mg/mL with warming)

Physical Description: White solid

Storage and Stability: Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.